Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PBK | Q96KB5 | 9/20 | 0.39 |
| ▸ | CD38 | P28907 | 3/20 | 0.35 |
| ▸ | HPGDS | O60760 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | TAF1 | P21675 | 1/20 | 0.34 |
| ▸ | CECR2 | Q9BXF3 | 1/20 | 0.34 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.34 |
| ▸ | TNKS | O95271 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26432911 | 0.81 | NPC1 (0.41) | PBKHPGDSTDP1NPC1LMNA | |
| SCHEMBL26432933 | 0.80 | TAF1 (0.39) | CD38TAF1CECR2BRD9HSD17B10 | |
| SCHEMBL26432887 | 0.79 | GRM5 (0.48) | CD38 | |
| SCHEMBL26432855 | 0.79 | KMT2A (0.47) | CD38NPC1LMNA | |
| SCHEMBL26432876 | 0.77 | CD38 (0.39) | CD38HPGDSTAF1CECR2BRD9 | |
| SCHEMBL26432948 | 0.74 | CD38 (0.42) | CD38TAF1CECR2BRD9SCN9A | |
| SCHEMBL26432962 | 0.74 | CD38 (0.41) | CD38HSD17B10NPC1 | |
| SCHEMBL32688184 | 0.73 | CD38 (0.64) | CD38 | |
| SCHEMBL23453743 | 0.71 | CRBN (0.55) | — | |
| SCHEMBL26432977 | 0.70 | L3MBTL1 (0.36) | SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11638704-B2 | Bicyclic compounds and their use in the treatment of cancer | TEMPEST THERAPEUTICS, INC. (US) | 2023-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11638704-B2 | Bicyclic compounds and their use in the treatment of cancer | PTGER4, PTGER1, PTGER3 | PBK 1267/4885CD38 1709/4885HPGDS 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.